Characterization of erythropoietin and hepcidin in the regulation of persistent injury-associated anemia

Journal of Trauma and Acute Care Surgery

Volumn 81, Issue 4, 2016, Pages 705-712

  Alamo, Ines G ^a   Kannan, Kolenkode B ^a   Smith, Michael A ^a   Efron, Philip A ^a   Mohr, Alicia M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

chronic stress; erythropoiesis; erythropoietin receptor; iron; Trauma

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FERRITIN; HEPCIDIN; IRON; MESSENGER RNA;

ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CHRONIC STRESS; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; ERYTHROID PRECURSOR CELL; FERRITIN BLOOD LEVEL; HEMORRHAGIC SHOCK; IMMOBILIZATION STRESS; IRON BLOOD LEVEL; IRON DEPLETION; IRON STORAGE; LUNG CONTUSION; MALE; NONHUMAN; PERSISTENT INJURY ASSOCIATED ANEMIA; POSTTRAUMATIC COMPLICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; ANIMAL; BLOOD; BONE MARROW; COMPLICATION; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE; INJURY; LUNG INJURY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGICAL STRESS; PHYSIOLOGY; RANDOMIZATION; SPRAGUE DAWLEY RAT;

ANEMIA; ANIMALS; BONE MARROW; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIETIN; HEPCIDINS; LUNG INJURY; MALE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RESTRAINT, PHYSICAL; SHOCK, HEMORRHAGIC; STRESS, PHYSIOLOGICAL; WOUNDS AND INJURIES;

EID: 84978141548     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0000000000001163     Document Type: Conference Paper

References (43)

1. Bible LE, Pasupuleti LV, AlzateWD, GoreAV, SongKJ, Sifri ZC, Livingston DH, Mohr AM. Early propranolol administration to severely injured patients can improve bone marrow dysfunction. J Trauma Acute Care Surg. 2014;77 (1):54-60; discussion 59-60.
2. Napolitano LM. Scope of the problem: epidemiology of anemia and use of blood transfusions in critical care. Crit Care. 2004;8(Suppl 2):S1-S8.
3. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, MacIntyre NR, Shabot MM, Duh MS, Shapiro MJ. The CRIT Study: anemia and blood transfusion in the critically ill-current clinical practice in the United States. Crit Care Med. 2004;32(1):39-52.
4. Mohr AM, ElHassan IO, Hannoush EJ, Sifri ZC, Offin MD, Alzate WD, Rameshwar P, Livingston DH. Does beta blockade postinjury prevent bone marrow suppression? J Trauma. 2011;70(5):1043-1049; discussion 9-50.
5. Livingston DH, Anjaria D, Wu J, Hauser CJ, Chang V, Deitch EA, Rameshwar P. Bone marrow failure following severe injury in humans. Ann Surg. 2003;238(5):748-753.
6. Badami CD, Livingston DH, Sifri ZC, Caputo FJ, Bonilla L, Mohr AM, Deitch EA. Hematopoietic progenitor cells mobilize to the site of injury after trauma and hemorrhagic shock in rats. J Trauma. 2007;63(3):596-600; discussion 600?2.
7. Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA, Frenette PS. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell. 2006;124(2): 407-421.
8. Corwin HL, Gettinger A, Rodriguez RM, Pearl RG, Gubler KD, Enny C, Colton T, Corwin MJ. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med. 1999;27(11):2346-2350.
9. SihlerKC, Raghavendran K, WestermanM, YeW, Napolitano LM. Hepcidin in trauma: linking injury, inflammation, and anemia. J Trauma. 2010;69(4): 831-837.
10. Pieracci FM, Stovall RT, Jaouen B, Rodil M, Cappa A, Burlew CC, Holena DN, Maier R, Berry S, Jurkovich J, et al. A multicenter, randomized clinical trial of IViron supplementation for anemia of traumatic critical illness. Crit Care Med. 2014;42(9):2048-2057.
11. Rodriguez RM, Corwin HL, Gettinger A, Corwin MJ, Gubler D, Pearl RG. Nutritional deficiencies and blunted erythropoietin response as causes of the Amemia of critical illness. J Crit Care. 2001;16(1):36-41.
12. SasakiY, Noguchi-SasakiM, Yasuno H, Yorozu K, ShimonakaY. Erythropoietin stimulation decreases hepcidin expression through hematopoietic activity on bone marrow cells in mice. Int J Hematol. 2012;96(6):692-700.
13. Constantinescu SN, Keren T, Russ WP, Ubarretxena-Belandia I, Malka Y, Kubatzky KF, Engelman DM, Lodish HF, Henis YI. The erythropoietin receptor transmembrane domain mediates complex formation with viral anemic and polycythemic gp55 proteins. J Biol Chem. 2003;278(44): 43755-43763.
14. Socolovsky M, Nam H, Fleming MD, Haase VH, Brugnara C, Lodish HF. Ineffective erythropoiesis in Stat5a(?/?)5b(?/?) mice due to decreased survival of early erythroblasts. Blood. 2001;98(12):3261-3273.
15. Nalbant D, Saleh M, Goldman FD, Widness JA, Veng-Pedersen P. Evidence of receptor-mediated elimination of erythropoietin by analysis of erythropoietin receptor mRNA expression in bone marrow and erythropoietin clearance during anemia. J Pharmacol Exp Ther. 2010;333(2):528-532.
16. Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell. 1995;83(1):59-67.
17. Lin CS, Lim SK, D'AgatiV, Costantini F. Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. Genes Dev. 1996;10(2):154-164.
18. KieranMW, Perkins AC, Orkin SH, Zon LI. Thrombopoietin rescues in vitro erythroid colony formation from mouse embryos lacking the erythropoietin receptor. Proc Natl Acad Sci U S A. 1996;93(17):9126-9131.
19. Deitch EA, Sittig KM. A serial study of the erythropoietic response to thermal injury. Ann Surg. 1993;217(3):293-299.
20. Bible LE, Pasupuleti LV, Gore AV, Sifri ZC, Kannan KB, Mohr AM. Chronic restraint stress after injury and shock is associated with persistent anemia despite prolonged elevation in erythropoietin levels. J Trauma Acute Care Surg. 2015;79(1):91-96; discussion 6-7.
21. Hobisch-Hagen P, Wiedermann F, Mayr A, Fries D, Jelkmann W, Fuchs D, Hasibeder W, Mutz N, Klingler A, Schobersberger W. Blunted erythropoietic response to anemia in multiply traumatized patients. Crit Care Med. 2001;29(4):743-747.
22. von Ahsen N, Muller C, Serke S, Frei U, Eckardt KU. Important role of nondiagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients. Crit Care Med. 1999;27(12): 2630-2639.
23. Jelkmann I, Jelkmann W. Impact of erythropoietin on intensive care unit patients. Transfus Med Hemother. 2013;40(5):310-318.
24. Rogiers P, Zhang H, Leeman M, Nagler J, Neels H, Melot C, Vincent JL. Erythropoietin response is blunted in critically ill patients. Intensive Care Med. 1997;23(2):159-162.
25. van Iperen CE, Gaillard CA, Kraaijenhagen RJ, Braam BG, Marx JJ, van de Wiel A. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med. 2000; 28(8):2773-2778.
26. Lasocki S, Millot S, Andrieu V, Letteron P, Pilard N, Muzeau F, Thibaudeau O, Montravers P, Beaumont C. Phlebotomies or erythropoietin injections allow mobilization of iron stores in a mouse model mimicking intensive care anemia. Crit Care Med. 2008;36(8):2388-2394.
27. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110(7):1037-1044.
28. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood. 2006; 108(12):3730-3735.
29. Bateman AP, McArdle F, Walsh TS. Time course of anemia during six months follow up following intensive care discharge and factors associated with impaired recovery of erythropoiesis. Crit Care Med. 2009;37(6): 1906-1912.
30. Molina PE. Neurobiology of the stress response: contribution of the sympathetic nervous system to the neuroimmune axis in traumatic injury. Shock. 2005;24(1):3-10.
31. Robinson Y, Matenov A, Tschoke SK, Weimann A, Oberholzer A, Ertel W, Hostmann A. Impaired erythropoiesis after haemorrhagic shock in mice is associated with erythroid progenitor apoptosis in vivo. Acta Anaesthesiol Scand. 2008;52(5):605-613.
32. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, Corwin MJ, Colton T, Group EPOCCT. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA. 2002;288(22):2827-2835.
33. Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, An R, Bowers PJ, Burton P, Klausner MA, Corwin MJ, EPO Critical Care Trials Group. Efficacy and safety of epoietin alfa in critically ill patients. N Engl J Med. 2007;357(10):965-976.
34. Elliott S, Pham E, Macdougall IC. Erythropoietins: a commonmechanismof action. Exp Hematol. 2008;36(12):1573-1584.
35. Pontikoglou C, Liapakis G, Pyrovolaki K, Papadakis M, Bux J, Eliopoulos GD, Papadaki HA. Evidence for downregulation of erythropoietin receptor in bone marrow erythroid cells of patients with chronic idiopathic neutropenia. Exp Hematol. 2006;34(10):1312-1322.
36. Pasupuleti LV, Cook KM, Sifri ZC, Alzate WD, Livingston DH, Mohr AM. Do all beta-blockers attenuate the excess hematopoietic progenitor cell mobilization from the bone marrow following trauma/hemorrhagic shock? J Trauma Acute Care Surg. 2014;76(4):970-975.
37. Baranski GM, Pasupuleti LV, Sifri ZC, Cook KM, AlzateWD, Rameshwar P, Livingston DH, Mohr AM. Beta blockade protection of bone marrow following injury: a critical link between heart rate and immunomodulation. J BoneMarrow Res. 2013;1.
38. Pirie K, Myles P, Wood E. Anemia and iron-restricted erythropoiesis in traumatic critical illness. J Trauma Acute Care Surg. 2016;80(3):538-545.
39. Fein E, Merle U, Ehehalt R, Herrmann T, Kulaksiz H. Regulation of hepcidin in HepG2 and RINm5F cells. Peptides. 2007;28(5):951-957.
40. Nicolas G, Viatte L, Bennoun M, Beaumont C, Kahn A, Vaulont S. Hepcidin, a new iron regulatory peptide. Blood Cells Mol Dis. 2002;29(3): 327-335.
41. Shike H, Lauth X, Westerman ME, Ostland VE, Carlberg JM, Van Olst JC, Shimizu C, Bulet P, Burns JC. Bass hepcidin is a novel antimicrobial peptide induced by bacterial challenge. Eur J Biochem. 2002;269(8):2232-2237.
42. Kelley-Loughnane N, Sabla GE, Ley-Ebert C, Aronow BJ, Bezerra JA. Independent and overlapping transcriptional activation during liver development and regeneration in mice. Hepatology. 2002;35(3):525-534.
43. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117(17): 4425-4433.